AC Immune
ACIU
33 hedge funds and large institutions have $33M invested in AC Immune in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 8 closing their positions.
1,350% more call options, than puts
Call options by funds: $29K | Put options by funds: $2K
10% more capital invested
Capital invested by funds: $30.1M → $33M (+$2.88M)
0.81% less ownership
Funds ownership: 17.67% → 16.86% (-0.81%)
11% less funds holding
Funds holding: 37 → 33 (-4)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$2.01M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$572K |
| 3 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
+$54K |
| 4 |
Millennium Management
New York
|
+$23.7K |
| 5 |
Renaissance Technologies
New York
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.04M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.11M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$379K |
| 4 |
E
Ergoteles
New York
|
-$122K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$110K |
ACIU Hedge Fund Activity: Q1 2023 in Review
33 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q1 2023, worth a combined $33M — up 9.5% from $30.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ACIU and 5 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Citigroup, opening a new position worth an estimated $2.01M. The largest seller was Artal Group, exiting entirely with an estimated $2.04M sold.
- 33 institutional investors held AC Immune (ACIU) as of Q1 2023, down from 37 in Q4 2022.
- Funds reported $33M of AC Immune stock for Q1 2023, up 9.5% quarter-over-quarter.
- 5 funds opened new AC Immune positions in Q1 2023 and 8 closed out, a net change of -3 holders.
- The largest AC Immune buyer in Q1 2023 was Citigroup, an estimated $2.01M added.
- The largest AC Immune seller in Q1 2023 was Artal Group, an estimated $2.04M sold.
Based on aggregated 13F filings for Q1 2023.